Medpace Holdings Inc. misled the public by overstating projected demand for its clinical trial services, an investor alleges in a proposed class action over a 16% selloff attributed to backlog concerns.
Medpace and its top executives “knew or deliberately disregarded that the therapeutic segments wherein Medpace was observing growth” might not stay consistent in the fourth quarter of the 2025 fiscal year, investor Jan Durbin says. She filed her complaint Monday in the US District Court for the Southern District of Ohio.
The Cincinnati-based clinical contract research group has a market capitalization of more than $14 billion.
“Medpace frequently claimed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.